Clinical Trial Application (CTA)
in Thailand
Clinical trials involving investigational medicinal products generally require regulatory approval before initiation.
Sponsors conducting studies in Thailand must comply with
-
Thai FDA requirements
-
Good Clinical Practice (ICH-GCP)
-
Local ethics committee requirements
-
Human research protection regulations
Step 1 – Regulatory Assessment
A typical CTA process includes:
Determine whether Thai FDA approval is required based on:
-
Product type
-
Study objectives
-
Development phase
-
Investigational status
Step 3 – Ethics Committee Approval
Ethics review focuses on:
Clinical studies involving human participants require review and approval by an Institutional Review Board (IRB) or Ethics Committee before enrollment begins.
-
Subject safety
-
Risk-benefit assessment
-
Informed consent
-
Patient confidentiality
-
Scientific validity
Step 2 – Prepare CTA Documentation
Typical submission documents include:
-
Clinical trial protocol
-
Investigator's Brochure
-
Investigational Medicinal Product Dossier (IMPD), where applicable
-
Chemistry, Manufacturing and Controls (CMC) information
-
Informed Consent Forms
-
Case Report Forms
-
Investigator qualifications
-
Insurance documentation
-
Safety information
Step 4 – Thai FDA Submission
After dossier completion, sponsors submit the CTA to the Thai FDA.
The authority may request clarification or additional documentation during review.
Step 5 – Trial Initiation
Following all required approvals:
-
Study sites are activated.
-
Investigators are trained.
-
Participant recruitment begins.
-
Safety reporting and monitoring continue throughout the study.
Sponsors must maintain ongoing regulatory compliance during the entire trial.
Common Regulatory Challenges
Companies entering the Thai market often encounter challenges such as:
-
Incorrect product classification
-
Incomplete technical documentation
-
Insufficient clinical evidence
-
Labeling non-compliance
-
Delayed responses to regulatory questions
-
Changing regulatory requirements
-
Lack of local regulatory expertise
Early regulatory planning can significantly reduce these risks.